BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 24130502)

  • 1. Cooperation between RUNX1-ETO9a and novel transcriptional partner KLF6 in upregulation of Alox5 in acute myeloid leukemia.
    DeKelver RC; Lewin B; Lam K; Komeno Y; Yan M; Rundle C; Lo MC; Zhang DE
    PLoS Genet; 2013; 9(10):e1003765. PubMed ID: 24130502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RUNX1-ETO induces a type I interferon response which negatively effects t(8;21)-induced increased self-renewal and leukemia development.
    DeKelver RC; Lewin B; Weng S; Yan M; Biggs J; Zhang DE
    Leuk Lymphoma; 2014 Apr; 55(4):884-91. PubMed ID: 23772668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A previously unidentified alternatively spliced isoform of t(8;21) transcript promotes leukemogenesis.
    Yan M; Kanbe E; Peterson LF; Boyapati A; Miao Y; Wang Y; Chen IM; Chen Z; Rowley JD; Willman CL; Zhang DE
    Nat Med; 2006 Aug; 12(8):945-9. PubMed ID: 16892037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histone deacetylase 3 preferentially binds and collaborates with the transcription factor RUNX1 to repress AML1-ETO-dependent transcription in t(8;21) AML.
    Guo C; Li J; Steinauer N; Wong M; Wu B; Dickson A; Kalkum M; Zhang J
    J Biol Chem; 2020 Mar; 295(13):4212-4223. PubMed ID: 32071087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RUNX1/AML1 DNA-binding domain and ETO/MTG8 NHR2-dimerization domain are critical to AML1-ETO9a leukemogenesis.
    Yan M; Ahn EY; Hiebert SW; Zhang DE
    Blood; 2009 Jan; 113(4):883-6. PubMed ID: 19036704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RUNX1 inhibits proliferation and induces apoptosis of t(8;21) leukemia cells
    Liu S; Xing Y; Lu W; Li S; Tian Z; Xing H; Tang K; Xu Y; Rao Q; Wang M; Wang J
    Haematologica; 2019 Aug; 104(8):1597-1607. PubMed ID: 30792202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An AML1-ETO/miR-29b-1 regulatory circuit modulates phenotypic properties of acute myeloid leukemia cells.
    Zaidi SK; Perez AW; White ES; Lian JB; Stein JL; Stein GS
    Oncotarget; 2017 Jun; 8(25):39994-40005. PubMed ID: 28611288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The leukemogenic t(8;21) fusion protein AML1-ETO controls rRNA genes and associates with nucleolar-organizing regions at mitotic chromosomes.
    Bakshi R; Zaidi SK; Pande S; Hassan MQ; Young DW; Montecino M; Lian JB; van Wijnen AJ; Stein JL; Stein GS
    J Cell Sci; 2008 Dec; 121(Pt 23):3981-90. PubMed ID: 19001502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Definition of a small core transcriptional circuit regulated by AML1-ETO.
    Stengel KR; Ellis JD; Spielman CL; Bomber ML; Hiebert SW
    Mol Cell; 2021 Feb; 81(3):530-545.e5. PubMed ID: 33382982
    [TBL] [Abstract][Full Text] [Related]  

  • 10. UBASH3B/Sts-1-CBL axis regulates myeloid proliferation in human preleukemia induced by AML1-ETO.
    Goyama S; Schibler J; Gasilina A; Shrestha M; Lin S; Link KA; Chen J; Whitman SP; Bloomfield CD; Nicolet D; Assi SA; Ptasinska A; Heidenreich O; Bonifer C; Kitamura T; Nassar NN; Mulloy JC
    Leukemia; 2016 Mar; 30(3):728-39. PubMed ID: 26449661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Depletion of RUNX1/ETO in t(8;21) AML cells leads to genome-wide changes in chromatin structure and transcription factor binding.
    Ptasinska A; Assi SA; Mannari D; James SR; Williamson D; Dunne J; Hoogenkamp M; Wu M; Care M; McNeill H; Cauchy P; Cullen M; Tooze RM; Tenen DG; Young BD; Cockerill PN; Westhead DR; Heidenreich O; Bonifer C
    Leukemia; 2012 Aug; 26(8):1829-41. PubMed ID: 22343733
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute myeloid leukemia with the 8q22;21q22 translocation: secondary mutational events and alternative t(8;21) transcripts.
    Peterson LF; Boyapati A; Ahn EY; Biggs JR; Okumura AJ; Lo MC; Yan M; Zhang DE
    Blood; 2007 Aug; 110(3):799-805. PubMed ID: 17412887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Attenuation of AML1-ETO cellular dysregulation correlates with increased leukemogenic potential.
    DeKelver RC; Yan M; Ahn EY; Shia WJ; Speck NA; Zhang DE
    Blood; 2013 May; 121(18):3714-7. PubMed ID: 23426948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AML-1/ETO fusion protein is a dominant negative inhibitor of transcriptional repression by the promyelocytic leukemia zinc finger protein.
    Melnick A; Carlile GW; McConnell MJ; Polinger A; Hiebert SW; Licht JD
    Blood; 2000 Dec; 96(12):3939-47. PubMed ID: 11090081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AML1/ETO proteins control POU4F1/BRN3A expression and function in t(8;21) acute myeloid leukemia.
    Dunne J; Gascoyne DM; Lister TA; Brady HJ; Heidenreich O; Young BD
    Cancer Res; 2010 May; 70(10):3985-95. PubMed ID: 20460523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Compatibility of RUNX1/ETO fusion protein modules driving CD34+ human progenitor cell expansion.
    Chen-Wichmann L; Shvartsman M; Preiss C; Hockings C; Windisch R; Redondo Monte E; Leubolt G; Spiekermann K; Lausen J; Brendel C; Grez M; Greif PA; Wichmann C
    Oncogene; 2019 Jan; 38(2):261-272. PubMed ID: 30093631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationships between AML1-ETO and MLL-AF9 fusion gene expressions and hematological parameters in acute myeloid leukemia.
    Muddathir ARM; Hamid TAM; Mohamed Elamin E; Khabour OF
    Gulf J Oncolog; 2020 Sep; 1(34):65-69. PubMed ID: 33431365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Hematopoietic Transcription Factors RUNX1 and ERG Prevent AML1-ETO Oncogene Overexpression and Onset of the Apoptosis Program in t(8;21) AMLs.
    Mandoli A; Singh AA; Prange KHM; Tijchon E; Oerlemans M; Dirks R; Ter Huurne M; Wierenga ATJ; Janssen-Megens EM; Berentsen K; Sharifi N; Kim B; Matarese F; Nguyen LN; Hubner NC; Rao NA; van den Akker E; Altucci L; Vellenga E; Stunnenberg HG; Martens JHA
    Cell Rep; 2016 Nov; 17(8):2087-2100. PubMed ID: 27851970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Persistence of multipotent progenitors expressing AML1/ETO transcripts in long-term remission patients with t(8;21) acute myelogenous leukemia.
    Miyamoto T; Nagafuji K; Akashi K; Harada M; Kyo T; Akashi T; Takenaka K; Mizuno S; Gondo H; Okamura T; Dohy H; Niho Y
    Blood; 1996 Jun; 87(11):4789-96. PubMed ID: 8639850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AML1/ETO sensitizes via TRAIL acute myeloid leukemia cells to the pro-apoptotic effects of hypoxia.
    Barbetti V; Tusa I; Cipolleschi MG; Rovida E; Dello Sbarba P
    Cell Death Dis; 2013 Mar; 4(3):e536. PubMed ID: 23492767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.